卵巢透明细胞癌（OCCC）是表皮性卵巢癌的亚型，预后不良。然而，尚未建立有效的生物标志物用于预测不良事件，包括复发和不良预后。血清microRNA（miRNA）越来越被报道为预测患者情况有用，并被认为是癌症液体活检潜在的非侵入性来源。因此，本研究旨在评估来自OCCC患者的血清miRNA谱，并建立预测预后的生物标志物。使用了包含卵巢肿瘤患者术前血清miRNA谱的GSE106817，并对临床信息进行了调查。总共包括66名OCCC患者，排除其他组织学亚型或不足的预后信息。此外，还检查了OCCC组织的miRNA谱。中位随访期为64.3（8.0-153.3）个月。基于多变量Cox回归分析和OCCC组织中miRNA的表达，miR-150-3p、miR-3195和miR-7704被选为与无进展生存期（PFS）和总生存期（OS）都有关联的miRNA候选物。然后，根据3种血清miRNA的表达值计算了预后指数。Kaplan-Meier生存分析表明，预后指数在PFS和OS方面显着预测（分别为p=0.004和p=0.012）。miR-150-3p、miR-3195和miR-7704的术前血清miRNA谱可以用于潜在预测OCCC患者的预后。 © 2023.亚洲妇科肿瘤学会、韩国妇科肿瘤学会和日本妇科肿瘤学会。

Ovarian clear cell carcinoma (OCCC) is a subtype of epithelial ovarian carcinoma with poor prognosis. However, no effective biomarkers have been established for predicting unfavorable events, including recurrence and poor prognoses. Serum microRNAs (miRNAs) have been increasingly reported to be useful in predicting a patient's condition and have been recognized as a potentially less-invasive source for liquid biopsy in cancer. Therefore, this study aimed to evaluate serum miRNA profiles from patients with OCCC and to establish biomarker for predicting the prognoses.The GSE106817, which included preoperative serum miRNA profiles of patients with ovarian tumors, was used, and clinical information was investigated. In all, 66 patients with OCCC were included, excluding those with other histological subtypes or insufficient prognostic information. Moreover, miRNA profiles of OCCC tissues were also examined.The median follow-up period was 64.3 (8.0-153.3) months. Based on multivariable Cox regression analyses and the expression of miRNAs in OCCC tissues, miR-150-3p, miR-3195, and miR-7704 were selected as miRNA candidates associated with both progression-free survival (PFS) and overall survival (OS). Then, the prognostic index was calculated based on expression values of 3 serum miRNAs. Kaplan-Meier survival analysis indicated that the prognostic index was significantly predictive of PFS and OS (p=0.004 and p=0.012, respectively).Preoperative serum miRNA profiles of miR-150-3p, miR-3195, and miR-7704 can be used to potentially predict the prognosis of patients with OCCC.© 2023. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology.